NSCLC Pathology and Molecular Testing- What Should Clinicians Know?

Overview

Classification of NSCLC has been rapidly evolving, owing in large part to increased attention to histologic features and common molecular alterations.  This program will review the key terminology in NSCLC pathology and discuss some of the logistical and technical elements of molecular testing that are important for incorporating molecular findings into clinical practice.

Date
Oct 10, 2017 -
Oct 10, 2017
Location

Online

After viewing this program attendees will be able to:

  • Identify and define key terms in the pathology of non-small cell lung cancer, and
  • Discuss the importance of multi-disciplinary communication in optimizing tissue management for molecular studies.

Dara L. Aisner, MD, PhD
Associate Professor, University of Colorado Department of Pathology, Director, Colorado Molecular Correlates Laboratory.

Program chair-Ramaswamy Govindan, MD
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.

For any inquiries, please contact [email protected].

After viewing this program attendees will be able to:

  • Identify and define key terms in the pathology of non-small cell lung cancer, and
  • Discuss the importance of multi-disciplinary communication in optimizing tissue management for molecular studies.

Dara L. Aisner, MD, PhD
Associate Professor, University of Colorado Department of Pathology, Director, Colorado Molecular Correlates Laboratory.

Program chair-Ramaswamy Govindan, MD
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.

For any inquiries, please contact [email protected].

Share

Interested in advertising and exhibit opportunities?